APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antihemophilic Factor Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antihemophilic Factor Drug Market Outlook and Growth Opportunities 2026

20 December 2025192 pages

Choose your research edition.

Industry ResearchAntihemophilic Factor Drug Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Antihemophilic Factor Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Antihemophilic Factor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antihemophilic Factor Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Antihemophilic Factor Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Antihemophilic Factor Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antihemophilic Factor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antihemophilic Factor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antihemophilic Factor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antihemophilic Factor Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antihemophilic Factor Drug market include Cigna, CSL Behring, GC Pharma, Grifols, Octapharma, Bayer, Hualan Biological Engineering, Pfizer and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antihemophilic Factor Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antihemophilic Factor Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antihemophilic Factor Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antihemophilic Factor Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Antihemophilic Factor Drug Segment by Company

Cigna

CSL Behring

GC Pharma

Grifols

Octapharma

Bayer

Hualan Biological Engineering

Pfizer

Novo Nordisk

Sanofi

Shanghai RAAS blood products

Takeda

Antihemophilic Factor Drug Segment by Type

250 IU

500 IU

1000 IU

1500 IU

2000 IU

3000 IU

4000 IU

Other potencies

Antihemophilic Factor Drug Segment by Application

Adult

Pediatric

Antihemophilic Factor Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Antihemophilic Factor Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Antihemophilic Factor Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antihemophilic Factor Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Antihemophilic Factor Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antihemophilic Factor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antihemophilic Factor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antihemophilic Factor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antihemophilic Factor Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antihemophilic Factor Drug industry.

Chapter 3: Detailed analysis of Antihemophilic Factor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Antihemophilic Factor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Antihemophilic Factor Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antihemophilic Factor Drug Industry Trends Table 2. Antihemophilic Factor Drug Industry Drivers Table 3. Antihemophilic Factor Drug Industry Opportunities and Challenges Table 4. Antihemophilic Factor Drug Industry Restraints Table 5. Global Antihemophilic Factor Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antihemophilic Factor Drug Revenue Share by Company (2021-2026) Table 7. Global Antihemophilic Factor Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Antihemophilic Factor Drug Sales Volume Share by Company (2021-2026) Table 9. Global Antihemophilic Factor Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Antihemophilic Factor Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Antihemophilic Factor Drug Key Company Manufacturing Base & Headquarters Table 12. Global Antihemophilic Factor Drug Company, Product Type & Application Table 13. Global Antihemophilic Factor Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Antihemophilic Factor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 250 IU Table 18. Significant Companies of 500 IU Table 19. Significant Companies of 1000 IU Table 20. Significant Companies of 1500 IU Table 21. Significant Companies of 2000 IU Table 22. Significant Companies of 3000 IU Table 23. Significant Companies of 4000 IU Table 24. Significant Companies of Other potencies Table 25. Global Antihemophilic Factor Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 26. Global Antihemophilic Factor Drug Sales Volume by Type (2021-2026) & (W Units) Table 27. Global Antihemophilic Factor Drug Sales Volume by Type (2027-2032) & (W Units) Table 28. Global Antihemophilic Factor Drug Sales Volume Share by Type (2021-2026) Table 29. Global Antihemophilic Factor Drug Sales Volume Share by Type (2027-2032) Table 30. Global Antihemophilic Factor Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Antihemophilic Factor Drug Sales Value by Type (2021-2026) & (US$ Million) Table 32. Global Antihemophilic Factor Drug Sales Value by Type (2027-2032) & (US$ Million) Table 33. Global Antihemophilic Factor Drug Sales Value Share by Type (2021-2026) Table 34. Global Antihemophilic Factor Drug Sales Value Share by Type (2027-2032) Table 35. Significant Companies of Adult Table 36. Significant Companies of Pediatric Table 37. Global Antihemophilic Factor Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 38. Global Antihemophilic Factor Drug Sales Volume by Application (2021-2026) & (W Units) Table 39. Global Antihemophilic Factor Drug Sales Volume by Application (2027-2032) & (W Units) Table 40. Global Antihemophilic Factor Drug Sales Volume Share by Application (2021-2026) Table 41. Global Antihemophilic Factor Drug Sales Volume Share by Application (2027-2032) Table 42. Global Antihemophilic Factor Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Antihemophilic Factor Drug Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Antihemophilic Factor Drug Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Antihemophilic Factor Drug Sales Value Share by Application (2021-2026) Table 46. Global Antihemophilic Factor Drug Sales Value Share by Application (2027-2032) Table 47. Global Antihemophilic Factor Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 48. Global Antihemophilic Factor Drug Sales by Region (2021-2026) & (W Units) Table 49. Global Antihemophilic Factor Drug Sales Market Share by Region (2021-2026) Table 50. Global Antihemophilic Factor Drug Sales by Region (2027-2032) & (W Units) Table 51. Global Antihemophilic Factor Drug Sales Market Share by Region (2027-2032) Table 52. Global Antihemophilic Factor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Antihemophilic Factor Drug Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Antihemophilic Factor Drug Sales Value Share by Region (2021-2026) Table 55. Global Antihemophilic Factor Drug Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Antihemophilic Factor Drug Sales Value Share by Region (2027-2032) Table 57. Global Antihemophilic Factor Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Antihemophilic Factor Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Antihemophilic Factor Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. Global Antihemophilic Factor Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Antihemophilic Factor Drug Sales by Country (2021-2026) & (W Units) Table 62. Global Antihemophilic Factor Drug Sales Market Share by Country (2021-2026) Table 63. Global Antihemophilic Factor Drug Sales by Country (2027-2032) & (W Units) Table 64. Global Antihemophilic Factor Drug Sales Market Share by Country (2027-2032) Table 65. Global Antihemophilic Factor Drug Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Antihemophilic Factor Drug Sales Value Market Share by Country (2021-2026) Table 67. Global Antihemophilic Factor Drug Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Antihemophilic Factor Drug Sales Value Market Share by Country (2027-2032) Table 69. Cigna Company Information Table 70. Cigna Business Overview Table 71. Cigna Antihemophilic Factor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Cigna Antihemophilic Factor Drug Product Portfolio Table 73. Cigna Recent Development Table 74. CSL Behring Company Information Table 75. CSL Behring Business Overview Table 76. CSL Behring Antihemophilic Factor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. CSL Behring Antihemophilic Factor Drug Product Portfolio Table 78. CSL Behring Recent Development Table 79. GC Pharma Company Information Table 80. GC Pharma Business Overview Table 81. GC Pharma Antihemophilic Factor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. GC Pharma Antihemophilic Factor Drug Product Portfolio Table 83. GC Pharma Recent Development Table 84. Grifols Company Information Table 85. Grifols Business Overview Table 86. Grifols Antihemophilic Factor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Grifols Antihemophilic Factor Drug Product Portfolio Table 88. Grifols Recent Development Table 89. Octapharma Company Information Table 90. Octapharma Business Overview Table 91. Octapharma Antihemophilic Factor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Octapharma Antihemophilic Factor Drug Product Portfolio Table 93. Octapharma Recent Development Table 94. Bayer Company Information Table 95. Bayer Business Overview Table 96. Bayer Antihemophilic Factor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Bayer Antihemophilic Factor Drug Product Portfolio Table 98. Bayer Recent Development Table 99. Hualan Biological Engineering Company Information Table 100. Hualan Biological Engineering Business Overview Table 101. Hualan Biological Engineering Antihemophilic Factor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Hualan Biological Engineering Antihemophilic Factor Drug Product Portfolio Table 103. Hualan Biological Engineering Recent Development Table 104. Pfizer Company Information Table 105. Pfizer Business Overview Table 106. Pfizer Antihemophilic Factor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Pfizer Antihemophilic Factor Drug Product Portfolio Table 108. Pfizer Recent Development Table 109. Novo Nordisk Company Information Table 110. Novo Nordisk Business Overview Table 111. Novo Nordisk Antihemophilic Factor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Novo Nordisk Antihemophilic Factor Drug Product Portfolio Table 113. Novo Nordisk Recent Development Table 114. Sanofi Company Information Table 115. Sanofi Business Overview Table 116. Sanofi Antihemophilic Factor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Sanofi Antihemophilic Factor Drug Product Portfolio Table 118. Sanofi Recent Development Table 119. Shanghai RAAS blood products Company Information Table 120. Shanghai RAAS blood products Business Overview Table 121. Shanghai RAAS blood products Antihemophilic Factor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Shanghai RAAS blood products Antihemophilic Factor Drug Product Portfolio Table 123. Shanghai RAAS blood products Recent Development Table 124. Takeda Company Information Table 125. Takeda Business Overview Table 126. Takeda Antihemophilic Factor Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Takeda Antihemophilic Factor Drug Product Portfolio Table 128. Takeda Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Antihemophilic Factor Drug Distributors List Table 132. Antihemophilic Factor Drug Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Antihemophilic Factor Drug Product Image Figure 2. Global Antihemophilic Factor Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antihemophilic Factor Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Antihemophilic Factor Drug Sales (2021-2032) & (W Units) Figure 5. Global Antihemophilic Factor Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Antihemophilic Factor Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 250 IU Image Figure 10. 500 IU Image Figure 11. 1000 IU Image Figure 12. 1500 IU Image Figure 13. 2000 IU Image Figure 14. 3000 IU Image Figure 15. 4000 IU Image Figure 16. Other potencies Image Figure 17. Global Antihemophilic Factor Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 18. Global Antihemophilic Factor Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 19. Global Antihemophilic Factor Drug Sales Volume Share by Type (2021-2032) Figure 20. Global Antihemophilic Factor Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Antihemophilic Factor Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Antihemophilic Factor Drug Sales Value Share by Type (2021-2032) Figure 23. Adult Image Figure 24. Pediatric Image Figure 25. Global Antihemophilic Factor Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global Antihemophilic Factor Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Antihemophilic Factor Drug Sales Volume Share by Application (2021-2032) Figure 28. Global Antihemophilic Factor Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Antihemophilic Factor Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Antihemophilic Factor Drug Sales Value Share by Application (2021-2032) Figure 31. Global Antihemophilic Factor Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 32. Global Antihemophilic Factor Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Antihemophilic Factor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Antihemophilic Factor Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Antihemophilic Factor Drug Sales Value (2021-2032) & (US$ Million) Figure 36. North America Antihemophilic Factor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Antihemophilic Factor Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Antihemophilic Factor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Antihemophilic Factor Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Antihemophilic Factor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Antihemophilic Factor Drug Sales Value (2021-2032) & (US$ Million) Figure 42. South America Antihemophilic Factor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Antihemophilic Factor Drug Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Antihemophilic Factor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Antihemophilic Factor Drug Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Antihemophilic Factor Drug Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • 250 IU
  • 500 IU
  • 1000 IU
  • 1500 IU
  • 2000 IU
  • 3000 IU
  • 4000 IU
  • Other potencies
Applications
  • Adult
  • Pediatric
Companies covered
  • Cigna
  • CSL Behring
  • GC Pharma
  • Grifols
  • Octapharma
  • Bayer
  • Hualan Biological Engineering
  • Pfizer
  • Novo Nordisk
  • Sanofi
  • Shanghai RAAS blood products
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antihemophilic Factor Drug Sales Value (2021-2032)
  4. 1.2.2 Global Antihemophilic Factor Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Antihemophilic Factor Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Antihemophilic Factor Drug Market Dynamics
  1. 2.1 Antihemophilic Factor Drug Industry Trends
  2. 2.2 Antihemophilic Factor Drug Industry Drivers
  3. 2.3 Antihemophilic Factor Drug Industry Opportunities and Challenges
  4. 2.4 Antihemophilic Factor Drug Industry Restraints
3 Antihemophilic Factor Drug Market by Company
  1. 3.1 Global Antihemophilic Factor Drug Company Revenue Ranking in 2025
  2. 3.2 Global Antihemophilic Factor Drug Revenue by Company (2021-2026)
  3. 3.3 Global Antihemophilic Factor Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Antihemophilic Factor Drug Average Price by Company (2021-2026)
  5. 3.5 Global Antihemophilic Factor Drug Company Ranking (2024-2026)
  6. 3.6 Global Antihemophilic Factor Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Antihemophilic Factor Drug Company Product Type and Application
  8. 3.8 Global Antihemophilic Factor Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Antihemophilic Factor Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Antihemophilic Factor Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Antihemophilic Factor Drug Market by Type
  1. 4.1 Antihemophilic Factor Drug Type Introduction
  2. 4.1.1 250 IU
  3. 4.1.2 500 IU
  4. 4.1.3 1000 IU
  5. 4.1.4 1500 IU
  6. 4.1.5 2000 IU
  7. 4.1.6 3000 IU
  8. 4.1.7 4000 IU
  9. 4.1.8 Other potencies
  10. 4.2 Global Antihemophilic Factor Drug Sales Volume by Type
  11. 4.2.1 Global Antihemophilic Factor Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Antihemophilic Factor Drug Sales Volume by Type (2021-2032)
  13. 4.2.3 Global Antihemophilic Factor Drug Sales Volume Share by Type (2021-2032)
  14. 4.3 Global Antihemophilic Factor Drug Sales Value by Type
  15. 4.3.1 Global Antihemophilic Factor Drug Sales Value by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Antihemophilic Factor Drug Sales Value by Type (2021-2032)
  17. 4.3.3 Global Antihemophilic Factor Drug Sales Value Share by Type (2021-2032)
5 Antihemophilic Factor Drug Market by Application
  1. 5.1 Antihemophilic Factor Drug Application Introduction
  2. 5.1.1 Adult
  3. 5.1.2 Pediatric
  4. 5.2 Global Antihemophilic Factor Drug Sales Volume by Application
  5. 5.2.1 Global Antihemophilic Factor Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Antihemophilic Factor Drug Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Antihemophilic Factor Drug Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Antihemophilic Factor Drug Sales Value by Application
  9. 5.3.1 Global Antihemophilic Factor Drug Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Antihemophilic Factor Drug Sales Value by Application (2021-2032)
  11. 5.3.3 Global Antihemophilic Factor Drug Sales Value Share by Application (2021-2032)
6 Antihemophilic Factor Drug Regional Sales and Value Analysis
  1. 6.1 Global Antihemophilic Factor Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antihemophilic Factor Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Antihemophilic Factor Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Antihemophilic Factor Drug Sales by Region (2027-2032)
  5. 6.3 Global Antihemophilic Factor Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Antihemophilic Factor Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Antihemophilic Factor Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Antihemophilic Factor Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Antihemophilic Factor Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Antihemophilic Factor Drug Sales Value (2021-2032)
  12. 6.6.2 North America Antihemophilic Factor Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Antihemophilic Factor Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Antihemophilic Factor Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Antihemophilic Factor Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Antihemophilic Factor Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Antihemophilic Factor Drug Sales Value (2021-2032)
  21. 6.9.2 South America Antihemophilic Factor Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Antihemophilic Factor Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Antihemophilic Factor Drug Sales Value Share by Country, 2025 VS 2032
7 Antihemophilic Factor Drug Country-level Sales and Value Analysis
  1. 7.1 Global Antihemophilic Factor Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antihemophilic Factor Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Antihemophilic Factor Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Antihemophilic Factor Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Antihemophilic Factor Drug Sales by Country (2027-2032)
  6. 7.4 Global Antihemophilic Factor Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Antihemophilic Factor Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Antihemophilic Factor Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Antihemophilic Factor Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Antihemophilic Factor Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Antihemophilic Factor Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Cigna
  2. 8.1.1 Cigna Company Information
  3. 8.1.2 Cigna Business Overview
  4. 8.1.3 Cigna Antihemophilic Factor Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Cigna Antihemophilic Factor Drug Product Portfolio
  6. 8.1.5 Cigna Recent Developments
  7. 8.2 CSL Behring
  8. 8.2.1 CSL Behring Company Information
  9. 8.2.2 CSL Behring Business Overview
  10. 8.2.3 CSL Behring Antihemophilic Factor Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CSL Behring Antihemophilic Factor Drug Product Portfolio
  12. 8.2.5 CSL Behring Recent Developments
  13. 8.3 GC Pharma
  14. 8.3.1 GC Pharma Company Information
  15. 8.3.2 GC Pharma Business Overview
  16. 8.3.3 GC Pharma Antihemophilic Factor Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GC Pharma Antihemophilic Factor Drug Product Portfolio
  18. 8.3.5 GC Pharma Recent Developments
  19. 8.4 Grifols
  20. 8.4.1 Grifols Company Information
  21. 8.4.2 Grifols Business Overview
  22. 8.4.3 Grifols Antihemophilic Factor Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Grifols Antihemophilic Factor Drug Product Portfolio
  24. 8.4.5 Grifols Recent Developments
  25. 8.5 Octapharma
  26. 8.5.1 Octapharma Company Information
  27. 8.5.2 Octapharma Business Overview
  28. 8.5.3 Octapharma Antihemophilic Factor Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Octapharma Antihemophilic Factor Drug Product Portfolio
  30. 8.5.5 Octapharma Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Antihemophilic Factor Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Antihemophilic Factor Drug Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Hualan Biological Engineering
  38. 8.7.1 Hualan Biological Engineering Company Information
  39. 8.7.2 Hualan Biological Engineering Business Overview
  40. 8.7.3 Hualan Biological Engineering Antihemophilic Factor Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Hualan Biological Engineering Antihemophilic Factor Drug Product Portfolio
  42. 8.7.5 Hualan Biological Engineering Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Antihemophilic Factor Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Antihemophilic Factor Drug Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Novo Nordisk
  50. 8.9.1 Novo Nordisk Company Information
  51. 8.9.2 Novo Nordisk Business Overview
  52. 8.9.3 Novo Nordisk Antihemophilic Factor Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Novo Nordisk Antihemophilic Factor Drug Product Portfolio
  54. 8.9.5 Novo Nordisk Recent Developments
  55. 8.10 Sanofi
  56. 8.10.1 Sanofi Company Information
  57. 8.10.2 Sanofi Business Overview
  58. 8.10.3 Sanofi Antihemophilic Factor Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Antihemophilic Factor Drug Product Portfolio
  60. 8.10.5 Sanofi Recent Developments
  61. 8.11 Shanghai RAAS blood products
  62. 8.11.1 Shanghai RAAS blood products Company Information
  63. 8.11.2 Shanghai RAAS blood products Business Overview
  64. 8.11.3 Shanghai RAAS blood products Antihemophilic Factor Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Shanghai RAAS blood products Antihemophilic Factor Drug Product Portfolio
  66. 8.11.5 Shanghai RAAS blood products Recent Developments
  67. 8.12 Takeda
  68. 8.12.1 Takeda Company Information
  69. 8.12.2 Takeda Business Overview
  70. 8.12.3 Takeda Antihemophilic Factor Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Takeda Antihemophilic Factor Drug Product Portfolio
  72. 8.12.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antihemophilic Factor Drug Value Chain Analysis
  2. 9.1.1 Antihemophilic Factor Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antihemophilic Factor Drug Sales Mode & Process
  6. 9.2 Antihemophilic Factor Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antihemophilic Factor Drug Distributors
  9. 9.2.3 Antihemophilic Factor Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst